Oxcia is developing OGG1 inhibitors against severe lung diseases in collaboration with Swedish academia, Karolinska Institutet, Lund University, Uppsala University and Stockholm University.
Proof of principle has been demonstrated in mice, showing that therapeutic treatment with our tool compound, an OGG1 inhibitor, TH5487 significantly reduces lung inflammation.
Targeting OGG1 is a completely novel approach for treatment of inflammatory. The pro-inflammatory immune cells that drive auto-immunity and inflammation suffer from high level of oxidative stress and therefore require specific detoxification enzymes for survival and function. One enzyme of specific interest is OGG1, 8oxo guanine glycosylase1. Through binding to promoter regions, enriched in oxidized guanines, this enzyme recruits other proteins such as transcription factors, e.g. NF-Ƙβ to form complexes, promoting transcription of pro-inflammatory genes. Our OGG1 inhibitor TH5487 prevents OGG1 from binding to DNA and thereby dampening the inflammatory responses in animal models (Visnes et al, Science, Nov 16, 2018). http://science.sciencemag.org/content/362/6416/834
Helleday lab at the Karolinska Institute is advancing the lead optimization of OGG1 inhibitors to develop novel therapies for severe lung inflammation diseases with large medical need such as ARDS, COPD, severe non allergic asthma and idiopathic pulmonary fibrosis (IPF).
Oxcia is responsible for the business and market strategies, IPR and regulatory strategies of the project. Oxcia is open for partnership to enable development of potential therapies and launch of novel products.
Oxcia in collaboration with Karolinska Institutet, Lund University and Uppsala University, have been granted 5 Million SEK by Swelife and Vinnova in support of the OGG1 project. Swelife is a strategic innovation programme, funded by the Programme Partners and the Swedish Government via the Swedish innovation agency, Vinnova. Swelife support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.